(Q36645980)

15 August 2017

A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer (English)

1 reference

15 August 2017

1 reference

1 reference

1 reference

S L Cheeseman

1

1 reference

15 August 2017

S P Joel

2

1 reference

15 August 2017

J D Chester

3

1 reference

15 August 2017

G Wilson

4

1 reference

15 August 2017

J T Dent

5

1 reference

15 August 2017

F J Richards

6

1 reference

15 August 2017

M T Seymour

7

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

87

1 reference

15 August 2017

393-399

1 reference

15 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600467

15 August 2017

0 references

cites work

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376131

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376131

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376131

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376131

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376131

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376131

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376131

Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376131

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376131

Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376131

Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376131

Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376131

A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376131

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600467

CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR

21 January 2018

1 reference

12 December 2020

High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer

1 reference

12 December 2020

Cost of Treating Advanced Colorectal Cancer: A Retrospective Comparison of Treatment Regimens

1 reference

12 December 2020

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

12 December 2020

Role of lymphatic mapping and sentinel node biopsy in the detection of melanoma nodal metastases

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600467

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6600467

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

1 reference